Business
Blackstone Announces Final Close of Record $6.3 Billion Life Sciences Fund – the Largest Private Fund Dedicated to Life Sciences
NEW YORK & CAMBRIDGE, Mass., March 30, 2026--Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences VI ("BXLS VI"). BXLS VI was oversubscribed and closed at its hard cap of $6.3 billion of total capital commitments. It is the largest life sciences private fund ever raised and is nearly 40% larger than its predecessor vehicle.
About this update from Blackstone Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1651,"height":646,"url":"https://media.zenfs.com/en/business-wire.com/30b7d77e7e07f92b6c0d66b6f64fabfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hUfxLbI__4MqT3dE8GCS3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3Ng--/https://media.zenfs.com/en/business-wire.com/30b7d77e7e07f92b6c0d66b6f64fabfe","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/z7MVK82Nz1mK_zdffExr1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDA-/https://media.zenfs.com/en/business-wire.com/30b7d77e7e07f92b6c0d66b6f64fabfe","width":1200,"height":470}},"lazy":false},{"type":"text","content":"— Oversubscribed fund reflects strong track record","length":50,"tagName":"p"},{"type":"text","content":"NEW YORK & CAMBRIDGE, Mass., March 30, 2026--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences VI ("BXLS VI"). BXLS VI was oversubscribed and closed at its hard cap of $6.3 billion of total capital commitments. It is the largest life sciences private fund ever raised and is nearly 40% larger than its predecessor vehicle.","length":385,"tagName":"p"},{"type":"text","content":"Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences ("BXLS"), said, "We are grateful to the BXLS VI investors for their strong support of our strategies and the firm’s enduring conviction in the life sciences." He added, "Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices. This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world."","length":534,"tagName":"p"},{"type":"text","content":"Blackstone launched its dedicated BXLS platform in 2018 to invest across the life cycle of companies and products in the key life science sectors. With $15 billion in assets under management as of Q4 2025, BXLS leverages the team’s deep domain expertise, industry relationships globally and scale capital to help finance the development and commercialization of new medicines and technologies with the potential to transform patients’ lives. These include blockbuster medicines such as LEQVIO®, AMVUTTRA®, and ...